Versant Venture Capital VI, L.P.'s Form 4 filing
LENZ Therapeutics, Inc. (LENZ) · filed Jun 12, 2025
- Accession no.
- 0000950170-25-085490
- Filed
- Jun 12, 2025, 4:37 PM ET
- Trade date
- Jun 10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $10.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Venture Capital VII, L.P.CIK 0001750266 | 10% Owner |
| Versant Ventures VI GP-GP, LLCCIK 0001777652 | 10% Owner |
| Versant Ventures VI GP, L.P.CIK 0001777654 | 10% Owner |
| Versant Ventures VII GP, L.P.CIK 0001777655 | 10% Owner |
| Versant Ventures VII GP-GP, LLCCIK 0001777656 | 10% Owner |
| Versant Vantage II, L.P.CIK 0001832235 | 10% Owner |
| Versant Vantage II GP-GP, LLCCIK 0001839789 | 10% Owner |
| Versant Vantage II GP, L.P.CIK 0001839790 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Common Stock | SSaleDisposed | −350,000 | $29.00 | −$10,150,000 | 1,248,789 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.